Access cutting-edge neurofibromatosis 1 treatment through this clinical trial at a research site in Indianapolis. Study-provided care at no cost to qualified participants.
Access neurofibromatosis 1 specialists in Indianapolis at no cost
This study follows strict safety protocols and ethical guidelines
All study-related neurofibromatosis 1 treatment provided free
Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was based on the finding that selumetinib shrinks the majority of PN in children with NF1 and results in clinically meaningful benefit such as improvement in pain or range of motion. However, many morbidities, such as blindness or nerve damage, cannot be fully reversed with PN shrinkage. Therefore, there r
Sponsor: University of Alabama at Birmingham
Check if you qualify for this neurofibromatosis 1 clinical trial in Indianapolis, IN
If you're searching for neurofibromatosis 1 treatment options in Indianapolis, IN, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Indianapolis research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neurofibromatosis 1 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.